RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.24.20237719
DO 10.1101/2020.11.24.20237719
A1 Al-Thani, Mohamed H.
A1 Farag, Elmoubasher
A1 Bertollini, Roberto
A1 Al Romaihi, Hamad Eid
A1 Abdeen, Sami
A1 Abdelkarim, Ashraf
A1 Daraan, Faisal
A1 Ismail, Ahmed
A1 Mostafa, Nahid
A1 Sahl, Mohamed
A1 Suliman, Jinan
A1 Tayar, Elias
A1 Kasem, Hasan Ali
A1 Agsalog, Meynard J. A.
A1 Akkarathodiyil, Bassam K.
A1 Alkhalaf, Ayat A.
A1 Alakshar, Mohamed Morhaf M. H.
A1 Al-Qahtani, Abdulsalam Ali A. H.
A1 Al-Shedifat, Monther H. A.
A1 Ansari, Anas
A1 Ataalla, Ahmad Ali
A1 Chougule, Sandeep
A1 Gopinathan, Abhilash K. K. V.
A1 Poolakundan, Feroz J.
A1 Ranbhise, Sanjay U.
A1 Saefan, Saed M. A.
A1 Thaivalappil, Mohamed M.
A1 Thoyalil, Abubacker S.
A1 Umar, Inayath M.
A1 Kanaani, Zaina Al
A1 Khal, Abdullatif Al
A1 Kuwari, Einas Al
A1 Butt, Adeel A.
A1 Coyle, Peter
A1 Jeremijenko, Andrew
A1 Kaleeckal, Anvar Hassan
A1 Latif, Ali Nizar
A1 Shaik, Riyazuddin Mohammad
A1 Rahim, Hanan F. Abdul
A1 Yassine, Hadi M.
A1 Nasrallah, Gheyath K.
A1 Kuwari, Mohamed G. Al
A1 Chaghoury, Odette
A1 Chemaitelly, Hiam
A1 Abu-Raddad, Laith J.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/24/2020.11.24.20237719.abstract
AB Background Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population who comprise 60% of the total population. This study aimed to assess the proportions of ever and/or current infection in this population.Methods A cross-sectional population-based survey was conducted during July 26-September 09, 2020 to assess both anti-SARS-CoV-2 positivity through serological testing and polymerase chain reaction (PCR) positivity through PCR testing. Associations with antibody and PCR positivity were identified through regression analyses.Results Study included 2,641 participants, 69.3% of whom were <40 years of age. Anti-SARS-CoV-2 positivity was estimated at 55.3% (95% CI: 53.3-57.3%) and was significantly associated with nationality, geographic location, educational attainment, occupation, presence of symptoms in the two weeks preceding the survey, and previous infection diagnosis. PCR positivity was assessed at 11.3% (95% CI: 9.9-12.8%) and was significantly associated with geographic location, contact with an infected person, and reporting two or more symptoms. Infection positivity (antibody and/or PCR positive) was assessed at 60.6% (95% CI: 9.9-12.8%). The proportion of antibody-positive CMWs that had a prior SARS-CoV-2 diagnosis was 9.3% (95% CI: 7.9-11.0%). Only seven infections were ever severe and one was ever critical—an infection severity rate of 0.5% (95% CI: 0.2-1.0%).Conclusions Six in every 10 CMWs have been infected, suggestive of reaching the herd immunity threshold. Infection severity was low with only one in every 200 infections progressing to be severe or critical. Only one in every 10 infections had been previously diagnosed suggestive of mostly asymptomatic or minimally mild infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support provided by the Ministry of Public Health, Hamad Medical Corporation, and the Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Clinical Research Core, all at Weill Cornell Medicine-Qatar. The statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Hamad Medical Corporation (HMC) and Weill Cornell Medicine-Qatar Institutional Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in aggregate form within the manuscript.